Michael F. Tweedle PhD

Michael F. Tweedle PhD
ProfessorCollege of Medicinetweedle.5@osu.edu
712 Biomedical Research Tower 460 W 12th Avenue Columbus Ohio 43210
Phone:614-247-4427Fax:
  • Experimental Therapeutics

General Research Interest

Pharmaceuticals for biochemically targeted imaging and radiotherapy of cancer.

Research Description

Creation of new molecularly targeted pharmaceuticals that are visualized in vivo via any diagnostic imaging technologies: CT, MRI, Nuclear, Ultrasound or Light imaging. Synthetic, analytical, and radio-chemistry, and cell and small animal biology and micro imaging are practiced.  The goals of most projects are targeted imaging agents that are closely enough biochemically associated with the therapy that the therapy can be patient personalized. Primary focus is on cancer with a special interest in breast, prostate and neuroendocrine cancers, particularly as targeted with peptides. Current projects include several that use small hormonal peptide targets like Gastrin Releasing Peptide,  Vasoactive Intestinal Peptide, Somatostatin, neuropeptide Y, et. al.; and intra-operative surgical guidance with imaging. Collaborations are welcome involving  existing or new cancer targets.     

Transinstitutional Work

Work is ongoing with The Wright Center for Innovation in Imaging on hybrid imaging instrumentation, particularly SPECT/CT and PET/MRI co-registered dual function imager development. My experience in imaging pharmaceuticals will contribute to the development of drugs specifically tailored to these new instruments.  The imaging agents laboratory also participates with the Wright Center of Innovation in Biomedical Imaging and Cardinal Health in creation of a PET Center. The molecular imaging agents laboratory operates within the department of radiology, and is associated with the James CCCC and The Wright Center of Innovation in Biomedical Imaging, and collaborating with Bioengineering and other departments at the university. The lab will focus on basic and translational research projects where molecular imaging is very closely associated with targeted molecular therapy, such a therapeutic drug monitoring, systemic targeted radiotherapeutics, image directed nanodevices, and image guided surgery.

Current Publications

  • Shrivastava A, von Wronski M, Tweedle MF, Nunn ADIdentification of ideal peptides for heterovalent ligands.Methods Mol Biol 1088 97-105 1/1/2014
  • Yusof AM, Kothandaraman S, Zhang X, Saji M, Ringel MD, Tweedle MF, Phay JEDevelopment of a calcium-sensing receptor molecular imaging agent.Surgery 154 1378-84; discussion 1384 12/1/2013
  • Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, Phelps M, Martin EW Jr, Tweedle MFSite Specific Discrete PEGylation of (124)I-Labeled mCC49 Fab' Fragments Improves Tumor MicroPET/CT Imaging in Mice.Bioconjug Chem 24 1945-54 11/20/2013
  • Ding H, Yusof AM, Kothandaraman S, Saji M, Wang C, Kumar K, Milum K, Carleton M, Pan X, Ringel MD, Tweedle MF, Phay JELocalization of CaSR antagonists in CaSR-expressing medullary thyroid cancer.J Clin Endocrinol Metab 98 E1722-9 11/1/2013
  • Shrivastava A, Wang SH, Raju N, Gierach I, Ding H, Tweedle MFHeterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.Bioorg Med Chem Lett 23(3) 687-92 2/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu